表紙
市場調查報告書

血脂異常症治療藥的全球市場:2017-2021年

Global Dyslipidemia Drugs Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 481554
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
血脂異常症治療藥的全球市場:2017-2021年 Global Dyslipidemia Drugs Market 2017-2021
出版日期: 2017年03月15日內容資訊: 英文 70 Pages
簡介

全球血脂異常症治療藥市場預測在2017年到2021年間,將以5.27%的年複合成長率 (CAGR) 成長。

本報告提供全球血脂異常症治療藥的市場調查,提供血脂異常症概要,血脂異常症治療藥的開發平台分析,市場規模的變化與預測,藥物類別·地區別詳細分析,市場趨勢及市場成長的各種影響因素分析,競爭環境,並彙整主要供應商簡介等資料。

第1章 摘要整理

第2章 報告範圍

第3章 市場調查手法

第4章 簡介

  • 市場亮點

第5章 血脂異常症:概要

第6章 開發平台分析

第7章 市場環境

  • 市場概要
  • 波特的五力分析

第8章 市場分析:各類藥物

  • Statin
  • 膽固醇吸收抑制劑
  • 注射劑
  • 其他

第9章 地區分析

  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第10章 決策架構

第11章 市場促進因素與課題

  • 成長推進因素
  • 成長推進因素的影響:客戶類別
  • 市場課題
  • 課題的影響:客戶類別

第12章 市場趨勢

  • Statin利用的擴大
  • 聯合治療
  • OTC藥利用的擴大

第13章 供應商環境

  • 競爭模式

第14章 主要供應商分析

  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • 其他的有力供應商

第15章 附錄

目錄
Product Code: IRTNTR12273

About Dyslipidemia Drugs

Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.

Technavio's analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Alnylam Pharmaceuticals
  • Amarin Corporation
  • Amgen
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • Eli Lilly
  • Esperion Therapeutics
  • GlaxoSmithKline
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Lupin Pharmaceuticals

Market driver

  • Change in ATP guidelines for management of hypercholesterolemia.
  • For a full, detailed list, view our report

Market challenge

  • Drawbacks associated with current therapies.
  • For a full, detailed list, view our report

Market trend

  • Increased uptake of OTC drugs.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: An overview of dyslipidemia

PART 06: Pipeline analysis

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by drug class

  • Statins
  • Cholesterol absorption inhibitors
  • Dyslipidemia injectables
  • Others

PART 09: Geographical segmentation

  • Dyslipidemia drugs market in Americas
  • Dyslipidemia drugs market in EMEA
  • Dyslipidemia drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments

PART 12: Market trends

  • Increasing use of statins
  • Combination therapies
  • Increased uptake of OTC drugs

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Key customer segments
  • Exhibit 02: Overview of phase III pipeline molecules in global dyslipidemia drugs market
  • Exhibit 03: Pipeline analysis
  • Exhibit 04: Global dyslipidemia drugs market snapshot 2016
  • Exhibit 05: Global dyslipidemia drugs market 2016-2021 ($ millions)
  • Exhibit 06: Five forces analysis
  • Exhibit 07: Global dyslipidemia drugs market by drug class
  • Exhibit 08: Global statin market 2016-2021 ($ millions)
  • Exhibit 09: Global cholesterol absorption inhibitors market 2016-2021 ($ millions)
  • Exhibit 10: Global dyslipidemia injectables market 2016-2021 ($ millions)
  • Exhibit 11: Global dyslipidemia drugs market by geography 2016 and 2021
  • Exhibit 12: Dyslipidemia drugs market revenue by geography 2016-2021 ($ millions)
  • Exhibit 13: Market scenario in Americas
  • Exhibit 14: Dyslipidemia drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 15: Market scenario in EMEA
  • Exhibit 16: Dyslipidemia drugs market in the EMEA 2016-2021 ($ millions)
  • Exhibit 17: Market scenario in APAC
  • Exhibit 18: Dyslipidemia drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 19: Population aged 60 years and over: World and developed and developing regions (millions)
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Impact of challenges
  • Exhibit 22: Competitive structure analysis of global dyslipidemia drugs market 2016
  • Exhibit 23: Competitive analysis of global dyslipidemia drugs market 2016
  • Exhibit 24: Market penetration of various players in global dyslipidemia drugs market 2016
  • Exhibit 25: Aegerion Pharmaceuticals: Key highlights
  • Exhibit 26: Aegerion Pharmaceuticals: Strength assessment
  • Exhibit 27: Aegerion Pharmaceuticals: Strategy assessment
  • Exhibit 28: Aegerion Pharmaceuticals: Opportunity assessment
  • Exhibit 29: AstraZeneca: Key highlights
  • Exhibit 30: AstraZeneca: Strength assessment
  • Exhibit 31: AstraZeneca: Strategy assessment
  • Exhibit 32: AstraZeneca: Opportunity assessment
  • Exhibit 33: Merck: Key highlights
  • Exhibit 34: Merck: Strength assessment
  • Exhibit 35: Merck: Strategy assessment
  • Exhibit 36: Merck: Opportunity assessment
  • Exhibit 37: Pfizer: Key highlights
  • Exhibit 38: Pfizer: Strength assessment
  • Exhibit 39: Pfizer: Strategy assessment
  • Exhibit 40: Pfizer: Opportunity assessment
  • Exhibit 41: Sanofi: Key highlights
  • Exhibit 42: Sanofi: Strength assessment
  • Exhibit 43: Sanofi: Strategy assessment
  • Exhibit 44: Sanofi: Opportunity assessment